ARTICLE | Clinical News
Exforge HCT regulatory update
October 26, 2009 7:00 AM UTC
The European Commission approved an MAA from Novartis AG for Exforge HCT amlodipine/valsartan/hydrochlorothiazide as substitution therapy to treat essential hypertension in adults whose blood pressure...